Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, available data suggest that MGF-driven restoration of redox homeostasis represents a central mechanistic axis of its antitumor activity, rather than merely a downstream branch of apoptosis (84,85).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [84]
In the citing paper
“Activation of oncogenes, aberrant metabolism, mitochondrial dysfunction, and loss of the tumor suppressor p53 can all promote increased ROS accumulation in cancer cells 69.”
From Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) · cites this paper as [69]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272 · cited 1×
“This is consistent with the high incidence of p53 mutation or loss of p53 function in over 50% of human cancer”
Background
Research works printed but not linked: 1
- Kim, G. J., Chandrasekaran, K. & Morgan, W. F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 21, 361–367 (2006). · DOI · Paper page
Cited by
Items 201–300 of 1,014
Designing bioresponsive nanomaterials for intracellular self-assembly
Chagri, S., Ng, D. Y. W., & Weil, T. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00373-x · Cited by 261
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
Swords, R. T., Kelly, K. R., Smith, P. G., Garnsey, J. J., Mahalingam, D., Medina, E., Oberheu, K., Padmanabhan, S., O'Dwyer, M., Nawrocki, S. T., et al. (2010) · Blood · doi:10.1182/blood-2009-11-254862 · Cited by 274
Xu, J., Shi, R., Chen, G., Dong, S., Yang, P., Zhang, Z., Niu, N., Gai, S., He, F., Fu, Y., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00082 · Cited by 274
Fan, Y., Liu, S., Yi, Y., Rong, H., & Zhang, J. (2021) · ACS Nano · doi:10.1021/acsnano.0c06962 · Cited by 276
Peroxiredoxin 1 and its role in cell signaling
Neumann, C. A., Cao, J., & Manevich, Y. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10242 · Cited by 267
Zhang, X., Chen, L., Lim, K. H., Gonuguntla, S., Lim, K. W., Pranantyo, D., Yong, W. P., Yam, W. J. T., Low, Z., Teo, W. J., et al. (2019) · Advanced Materials · doi:10.1002/adma.201804540 · Cited by 273
Huang, Z., Wang, Y., Yao, D., Wu, J., Hu, Y., & Yuan, A. (2021) · Nature Communications · doi:10.1038/s41467-020-20243-8 · Cited by 272
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Mitochondria Targeting as an Effective Strategy for Cancer Therapy
Ghosh, P., Vidal, C., Dey, S., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093363 · Cited by 263
“Metabolic aberrations in cancer cells lead to the accumulation of ROS, which in turn causes biomolecular damage and cell death when present at high levels [37,38].”
BackgroundAn Activatable Prodrug for the Treatment of Metastatic Tumors
Kim, E.-J., Bhuniya, S., Lee, H., Kim, H. M., Cheong, C., Maiti, S., Hong, K. S., & Kim, J. S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5077684 · Cited by 268
Polycystic ovary syndrome and mitochondrial dysfunction
Zhang, J., Bao, Y., Zhou, X., & Zheng, L. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0509-4 · Cited by 258
Enhanced Antitumor Efficacy by a Cascade of Reactive Oxygen Species Generation and Drug Release
Wang, S., Yu, G., Wang, Z., Jacobson, O., Lin, L., Yang, W., Deng, H., He, Z., Liu, Y., Chen, Z., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201908997 · Cited by 270
System xc− and Thioredoxin Reductase 1 Cooperatively Rescue Glutathione Deficiency
Mandal, P. K., Seiler, A., Perisic, T., Kölle, P., Banjac Canak, A., Förster, H., Weiss, N., Kremmer, E., Lieberman, M. W., Bannai, S., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121327 · Cited by 269
Li, J., Li, Y., Wang, Y., Ke, W., Chen, W., Wang, W., & Ge, Z. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03531 · Cited by 263
Li, Y., Tan, C.-P., Zhang, W., He, L., Ji, L.-N., & Mao, Z.-W. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.070 · Cited by 267
“Mitochondria are the major source of intracellular ROS, and mitochondrial dysfunction is closely related to ROS accumulation in the process of apoptosis [59].”
BackgroundPatel, G. K., Khan, M. A., Bhardwaj, A., Srivastava, S. K., Zubair, H., Patton, M. C., Singh, S., Khushman, M., & Singh, A. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.18 · Cited by 266
“Generation of ROS by chemotherapeutic drugs is suggested to be one important mechanism for its cytotoxic efficacy (Trachootham et al, 2009; Donadelli et al, 2011).”
BackgroundRegulation of catalase expression in healthy and cancerous cells
Glorieux, C., Zamocky, M., Sandoval, J. M., Verrax, J., & Calderon, P. B. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.017 · Cited by 256
Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin
Gibellini, L., Pinti, M., Nasi, M., De Biasi, S., Roat, E., Bertoncelli, L., & Cossarizza, A. (2010) · Cancers · doi:10.3390/cancers2021288 · Cited by 263
“Because the overall redox homeostasis is maintained by the balance between ROS generation and elimination, exogenous compounds that increase ROS generation, or inhibit ROS elimination, can favor the accumulation of ROS in cancer cells, and hence induce cell damage or even cell death [67].”
BackgroundTransfer hydrogenation catalysis in cells as a new approach to anticancer drug design
Soldevila-Barreda, J. J., Romero-Canelón, I., Habtemariam, A., & Sadler, P. J. (2015) · Nature Communications · doi:10.1038/ncomms7582 · Cited by 262
Aminoferrocene-Based Prodrugs Activated by Reactive Oxygen Species
Hagen, H., Marzenell, P., Jentzsch, E., Wenz, F., Veldwijk, M. R., & Mokhir, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2014937 · Cited by 260
Do reactive oxygen species play a role in myeloid leukemias?
Hole, P. S., Darley, R. L., & Tonks, A. (2011) · Blood · doi:10.1182/blood-2011-01-326025 · Cited by 254
Lin, L., Song, J., Song, L., Ke, K., Liu, Y., Zhou, Z., Shen, Z., Li, J., Yang, Z., Tang, W., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201712027 · Cited by 260
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Classification of mitocans, anti-cancer drugs acting on mitochondria
Neuzil, J., Dong, L.-F., Rohlena, J., Truksa, J., & Ralph, S. J. (2013) · Mitochondrion · doi:10.1016/j.mito.2012.07.112 · Cited by 245
“However, the recent findings that tamoxifen also acts as a class 5 mitocan via targeting the mitochondrial CI (Moreira et al., 2006) endows it with a novel translational spin, such that its modification whereby it will localise primarily to mitochondria will give it an additional, thus far…”
BackgroundRole of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts
Averbeck, D., & Rodriguez-Lafrasse, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011047 · Cited by 232
Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway
Yamamoto, T., Takano, N., Ishiwata, K., Ohmura, M., Nagahata, Y., Matsuura, T., Kamata, A., Sakamoto, K., Nakanishi, T., Kubo, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms4480 · Cited by 250
Recent Advances on Reactive Oxygen Species-Responsive Delivery and Diagnosis System
Ye, H., Zhou, Y., Liu, X., Chen, Y., Duan, S., Zhu, R., Liu, Y., & Yin, L. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00628 · Cited by 251
Hammad, M., Raftari, M., Cesário, R., Salma, R., Godoy, P., Emami, S. N., & Haghdoost, S. (2023) · Antioxidants · doi:10.3390/antiox12071371 · Cited by 231
Chen, L., Xu, B., Liu, L., Luo, Y., Zhou, H., Chen, W., Shen, T., Han, X., Kontos, C. D., & Huang, S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.032 · Cited by 251
“In cells, ROS homeostasis is tightly controlled by the ROS-generating and -eliminating systems [45].”
BackgroundAl Ghouleh, I., Khoo, N. K. H., Knaus, U. G., Griendling, K. K., Touyz, R. M., Thannickal, V. J., Barchowsky, A., Nauseef, W. M., Kelley, E. E., Bauer, P. M., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.011 · Cited by 250
Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4032 · Cited by 243
Fiskus, W., Saba, N., Shen, M., Ghias, M., Liu, J., Gupta, S. D., Chauhan, L., Rao, R., Gunewardena, S., Schorno, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2033 · Cited by 248
“Cancer Res; 74(9) May 1, 2014 Cancer Research 2524”
InfluentialSelf-citationStafford, W. C., Peng, X., Olofsson, M. H., Zhang, X., Luci, D. K., Lu, L., Cheng, Q., Trésaugues, L., Dexheimer, T. S., Coussens, N. P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf7444 · Cited by 240
Qi, J., Fang, Y., Kwok, R. T. K., Zhang, X., Hu, X., Lam, J. W. Y., Ding, D., & Tang, B. Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b03062 · Cited by 246
Targeted scavenging of extracellular ROS relieves suppressive immunogenic cell death
Deng, H., Yang, W., Zhou, Z., Tian, R., Lin, L., Ma, Y., Song, J., & Chen, X. (2020) · Nature Communications · doi:10.1038/s41467-020-18745-6 · Cited by 241
Recent advances in responsive hydrogels for diabetic wound healing
Zhang, S., Ge, G., Qin, Y., Li, W., Dong, J., Mei, J., Ma, R., Zhang, X., Bai, J., Zhu, C., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100508 · Cited by 232
Allensworth, J. L., Evans, M. K., Bertucci, F., Aldrich, A. J., Festa, R. A., Finetti, P., Ueno, N. T., Safi, R., McDonnell, D. P., Thiele, D. J., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.007 · Cited by 240
Molecular mechanisms of anticancer effect of rutin
Imani, A., Maleki, N., Bohlouli, S., Kouhsoltani, M., Sharifi, S., & Maleki Dizaj, S. (2021) · Phytotherapy Research · doi:10.1002/ptr.6977 · Cited by 240
“…level of reactive oxygen species will probably lead to earlier achievement of cancerous cells to oxidative stress threshold compared to the normal cells, which can subsequently lead to death of cancer cells stimulated by oxidative stress (NavaneethaKrishnan et al., 2018; Trachootham et al., 2009).”
BackgroundHole, P. S., Zabkiewicz, J., Munje, C., Newton, Z., Pearn, L., White, P., Marquez, N., Hills, R. K., Burnett, A. K., Tonks, A., et al. (2013) · Blood · doi:10.1182/blood-2013-04-491944 · Cited by 234
“Reactive oxygen species (ROS) are a heterogeneous group of molecules and free radicals that are increasingly implicated in a variety of normal cellular processes(1) and are frequently elevated in cancer cells.(2) ROS are generated from multiple sources,(3) including the mitochondrial electron transport chain(4) or nic…”
BackgroundDenev, P. N., Kratchanov, C. G., Ciz, M., Lojek, A., & Kratchanova, M. G. (2012) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/j.1541-4337.2012.00198.x · Cited by 236
Amino acid metabolism in hematologic malignancies and the era of targeted therapy
Tabe, Y., Lorenzi, P. L., & Konopleva, M. (2019) · Blood · doi:10.1182/blood.2019001034 · Cited by 237
Moro-García, M. A., Mayo, J. C., Sainz, R. M., & Alonso-Arias, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00339 · Cited by 234
“In addition, NADPH, is one of the main thiol-dependent electron donors system in the cell and plays a critical role in the regulation of cellular redox environment and in a wide range of cellular pathways, including activation of transcription factors such as NF-κB, activator protein-1, p53, HIF-1, or the redox factor…”
BackgroundAdvances in nanomedicine for cancer starvation therapy
Yu, S., Chen, Z., Zeng, X., Chen, X., & Gu, Z. (2019) · Theranostics · doi:10.7150/thno.38261 · Cited by 242
“On the one hand, the overproduced H2O2 of glucose oxidation can cause systemic toxicity and lethal chain reactions through directly damaging cell membranes, proteins and DNA of normal cells [92, 93].”
Tian, Y., Xie, Q., He, J., Luo, X., Zhou, T., Liu, Y., Huang, Z., Tian, Y., Sun, D., & Yao, K. (2015) · BMC Cancer · doi:10.1186/1471-2407-15-1 · Cited by 239
“Reactive oxygen species (ROS) play an important role in cellular metabolism and cancer therapy [19,20].”
BackgroundXuan, W., Xia, Y., Li, T., Wang, L., Liu, Y., & Tan, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10755 · Cited by 240
Ahn, H. J., Kim, K. I., Hoan, N. N., Kim, C. H., Moon, E., Choi, K. S., Yang, S. S., & Lee, J.-S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086173 · Cited by 236
Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis
Wu, J. B., Shao, C., Li, X., Li, Q., Hu, P., Shi, C., Li, Y., Chen, Y.-T., Yin, F., Liao, C.-P., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70982 · Cited by 230
“ROS can predispose cancer cells to DNA damage and cause tumor initiation and progression (6).”
Yuan, Z., Cai, N., Du, Y., He, Y., & Yeung, E. S. (2014) · Analytical Chemistry · doi:10.1021/ac402158j · Cited by 237
Grasso, D., Zampieri, L. X., Capelôa, T., Van de Velde, J. A., & Sonveaux, P. (2020) · Cell Stress · doi:10.15698/cst2020.06.221 · Cited by 227
Shi, Y., Nikulenkov, F., Zawacka-Pankau, J., Li, H., Gabdoulline, R., Xu, J., Eriksson, S., Hedström, E., Issaeva, N., Kel, A., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.186 · Cited by 234
“Recent studies have revealed the dependency of cancers on redox-regulating mechanisms, such as the glutaredoxin and the thioredoxin systems, to be the cancerspecific vulnerability thereby offering a target for treatment of malignancies.(9,10) The NADPH-dependent selenoprotein thioredoxin reductase (TrxR), often overex…”
BackgroundHuang, K., Chen, Y., Zhang, R., Wu, Y., Ma, Y., Fang, X., & Shen, S. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0166-5 · Cited by 231
Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses
Jiang, L., Hickman, J. H., Wang, S.-J., & Gu, W. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1068479 · Cited by 231
“Cancer cells typically exhibit higher levels of ROS compared to their normal counterparts, and strategies to further increase ROS to induce cell death in transformed cells have been proposed.(20) To cope with enhanced ROS levels, however, cancer cells frequently upregulate SLC7A11 thereby strengthening their tolerance…”
BackgroundSynthesis, cellular evaluation, and mechanism of action of piperlongumine analogs
Adams, D. J., Dai, M., Pellegrino, G., Wagner, B. K., Stern, A. M., Shamji, A. F., & Schreiber, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212802109 · Cited by 228
Jiang, J., Wang, K., Chen, Y., Chen, H., Nice, E. C., & Huang, C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.36 · Cited by 228
Farha, A. K., Gan, R.-Y., Li, H.-B., Wu, D.-T., Atanasov, A. G., Gul, K., Zhang, J.-R., Yang, Q.-Q., & Corke, H. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1829541 · Cited by 225
Oncogenic pathways and the electron transport chain: a dangeROS liaison
Raimondi, V., Ciccarese, F., & Ciminale, V. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0651-y · Cited by 220
“Furthermore, highly proliferating, undifferentiated cancers display higher levels of GPDH activity than more differentiated cancers with low proliferative capacity.(96) Mitochondrial dihydro-orotate dehydrogenase (DHODH) is a FAD-linked enzyme that mediates the oxidation of dihydro-orotate to orotate, which fuels elec…”
BackgroundMolecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment
Semmler, M. L., Bekeschus, S., Schäfer, M., Bernhardt, T., Fischer, T., Witzke, K., Seebauer, C., Rebl, H., Grambow, E., Vollmar, B., et al. (2020) · Cancers · doi:10.3390/cancers12020269 · Cited by 220
“If the intracellular oxidative stress triggered by free radicals exceeds the amount that can be handled by the anti-oxidative defense system apoptosis will be induced through a signaling cascade [31].”
BackgroundSayin, V. I., LeBoeuf, S. E., Singh, S. X., Davidson, S. M., Biancur, D., Guzelhan, B. S., Alvarez, S. W., Wu, W. L., Karakousi, T. R., Zavitsanou, A. M., et al. (2017) · eLife · doi:10.7554/elife.28083 · Cited by 231
“To maintain oxidative homeostasis, cancer cells increase their antioxidant capacity (Trachootham et al., 2009).”
BackgroundCairns, R. A., Harris, I., McCracken, S., & Mak, T. W. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.012856 · Cited by 220
“…oxidative stress that occurs in p53-deficient cells suggests that using oxidative agents to induce lethal ROS levels might be an effective therapy (Trachootham et al. 2006, 2008, 2009), it seems that cancer cells have been selected for the evolution of alternative measures that allow them to…”
BackgroundKrstić, J., Trivanović, D., Mojsilović, S., & Santibanez, J. F. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/654594 · Cited by 225
Stafford, P., Abdelwahab, M. G., Kim, D. Y., Preul, M. C., Rho, J. M., & Scheck, A. C. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-74 · Cited by 224
Tadros, S., Shukla, S. K., King, R. J., Gunda, V., Vernucci, E., Abrego, J., Chaika, N. V., Yu, F., Lazenby, A. J., Berim, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3062 · Cited by 221
From structure to redox: The diverse functional roles of disulfides and implications in disease
Bechtel, T. J., & Weerapana, E. (2017) · PROTEOMICS · doi:10.1002/pmic.201600391 · Cited by 211
Wu, Q., He, Z., Wang, X., Zhang, Q., Wei, Q., Ma, S., Ma, C., Li, J., & Wang, Q. (2019) · Nature Communications · doi:10.1038/s41467-018-08234-2 · Cited by 221
ROS-Mediated Cancer Cell Killing through Dietary Phytochemicals
NavaneethaKrishnan, S., Rosales, J. L., & Lee, K.-Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9051542 · Cited by 217
“Thus, additional surge in ROS level is likely to cause cancer cells to reach their oxidative stress threshold sooner than normal cells, resulting in oxidative stress-induced cancer cell death [7, 8].”
BackgroundReactive Oxygen Species in Photodynamic Therapy: Mechanisms of Their Generation and Potentiation
Dąbrowski, J. M. (2017) · Advances in Inorganic Chemistry · doi:10.1016/bs.adioch.2017.03.002 · Cited by 211
Lei, S., Zhang, J., Blum, N. T., Li, M., Zhang, D.-Y., Yin, W., Zhao, F., Lin, J., & Huang, P. (2022) · Nature Communications · doi:10.1038/s41467-022-29082-1 · Cited by 220
Self-citationBiomimetic Liposomal Nanoplatinum for Targeted Cancer Chemophototherapy
Liu, X., Dong, X., Yang, S., Lai, X., Liu, H., Gao, Y., Feng, H., Zhu, M., Yuan, Y., Lu, Q., et al. (2021) · Advanced Science · doi:10.1002/advs.202003679 · Cited by 220
Arginine Starvation Impairs Mitochondrial Respiratory Function in ASS1-Deficient Breast Cancer Cells
Qiu, F., Chen, Y.-R., Liu, X., Chu, C.-Y., Shen, L.-J., Xu, J., Gaur, S., Forman, H. J., Zhang, H., Zheng, S., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004761 · Cited by 217
“4G) that favors tumorigenesis because even a moderate increase in ROS production can promote cell proliferation and tumorigenesis (79).”
BackgroundPelicano, H., Zhang, W., Liu, J., Hammoudi, N., Dai, J., Xu, R.-H., Pusztai, L., & Huang, P. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0434-6 · Cited by 212
“Nevertheless, elevated ROS generation in cancer cells is correlated with the aggressiveness of tumors and poor prognosis [51].”
BackgroundSelf-citationTang, J.-Y., Ou-Yang, F., Hou, M.-F., Huang, H.-W., Wang, H.-R., Li, K.-T., Fayyaz, S., Shu, C.-W., & Chang, H.-W. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.08.010 · Cited by 218
Interfacing Materials Science and Biology for Drug Carrier Design
Such, G. K., Yan, Y., Johnston, A. P. R., Gunawan, S. T., & Caruso, F. (2015) · Advanced Materials · doi:10.1002/adma.201405084 · Cited by 220
Li, J., Dirisala, A., Ge, Z., Wang, Y., Yin, W., Ke, W., Toh, K., Xie, J., Matsumoto, Y., Anraku, Y., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706964 · Cited by 219
Rauf, A., Khalil, A. A., Awadallah, S., Khan, S. A., Abu‐Izneid, T., Kamran, M., Hemeg, H. A., Mubarak, M. S., Khalid, A., & Wilairatana, P. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.3784 · Cited by 193
“Along this line, ROS can create DNA damage that stimulates the p53 gene in normal cells, activating it, where DNA repair and stress responses are two examples (Trachootham et al., 2009 ).”
BackgroundImproving cancer therapy through the nanomaterials-assisted alleviation of hypoxia
Sahu, A., Kwon, I., & Tae, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119578 · Cited by 217
The Mitochondrion as an Emerging Therapeutic Target in Cancer
Roth, K. G., Mambetsariev, I., Kulkarni, P., & Salgia, R. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.009 · Cited by 216
An, J., Hu, Y.-G., Cheng, K., Li, C., Hou, X.-L., Wang, G.-L., Zhang, X.-S., Liu, B., Zhao, Y.-D., & Zhang, M.-Z. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119761 · Cited by 217
Metal complex catalysis in living biological systems
Sasmal, P. K., Streu, C. N., & Meggers, E. (2013) · Chem. Commun. · doi:10.1039/c2cc37832a · Cited by 217
Hypoxic Radioresistance: Can ROS Be the Key to Overcome It?
Wang, H., Jiang, H., Van De Gucht, M., & De Ridder, M. (2019) · Cancers · doi:10.3390/cancers11010112 · Cited by 203
“Cells produce ROS at diverse sites, including mitochondria, endoplasmic reticulum, peroxisomes, and the family of Nicotinamide Adenine Denucleotide Phosphate Reduced Form (NADPH) oxidases [29].”
BackgroundArsenene-mediated multiple independently targeted reactive oxygen species burst for cancer therapy
Kong, N., Zhang, H., Feng, C., Liu, C., Xiao, Y., Zhang, X., Mei, L., Kim, J. S., Tao, W., & Ji, X. (2021) · Nature Communications · doi:10.1038/s41467-021-24961-5 · Cited by 217
A systems view of epithelial–mesenchymal transition signaling states
Thomson, S., Petti, F., Sujka-Kwok, I., Mercado, P., Bean, J., Monaghan, M., Seymour, S. L., Argast, G. M., Epstein, D. M., & Haley, J. D. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9367-3 · Cited by 211
“Altered metabolism of cancer cells often leads to the excess production of reactive oxygen species (ROS) which are scavenged in part by the glutathione and thioredoxin pathways [99].”
BackgroundLarasati, Y. A., Yoneda-Kato, N., Nakamae, I., Yokoyama, T., Meiyanto, E., & Kato, J.-Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-20179-6 · Cited by 209
Hasan, M., Belhaj, N., Benachour, H., Barberi-Heyob, M., Kahn, C. J. F., Jabbari, E., Linder, M., & Arab-Tehrany, E. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.12.007 · Cited by 209
GSH and H2O2 Co‐Activatable Mitochondria‐Targeted Photodynamic Therapy under Normoxia and Hypoxia
Sun, J., Du, K., Diao, J., Cai, X., Feng, F., & Wang, S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003895 · Cited by 215
Beyond Warburg effect – dual metabolic nature of cancer cells
Xie, J., Wu, H., Dai, C., Pan, Q., Ding, Z., Hu, D., Ji, B., Luo, Y., & Hu, X. (2014) · Scientific Reports · doi:10.1038/srep04927 · Cited by 207
Yan, D., Talbot, A., Nourmohammadi, N., Sherman, J. H., Cheng, X., & Keidar, M. (2015) · Biointerphases · doi:10.1116/1.4938020 · Cited by 206
Regulation of Nrf2/ARE Pathway by Dietary Flavonoids: A Friend or Foe for Cancer Management?
L. Suraweera, T., Rupasinghe, H. P. V., Dellaire, G., & Xu, Z. (2020) · Antioxidants · doi:10.3390/antiox9100973 · Cited by 192
“, cisplatin, doxorubicin, and 2-methoxyestradiol [27,29,30].”
The Role of Oxidative Stress and Its Counteractive Utility in Colorectal Cancer (CRC)
Basak, D., Uddin, M. N., & Hancock, J. (2020) · Cancers · doi:10.3390/cancers12113336 · Cited by 211
“Owing to their inherent elevated oxidative stress, cancer cells are heavily reliant on antioxidants for their survival that makes them increasingly vulnerable to exogenous ROS modulating agents, as illustrated in Figure 4 [203,204].”
BackgroundYang, J., Griffin, A., Qiang, Z., & Ren, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01243-0 · Cited by 196
Wang, P., Tang, Q., Zhang, L., Xu, M., Sun, L., Sun, S., Zhang, J., Wang, S., & Liang, X. (2021) · ACS Nano · doi:10.1021/acsnano.1c00616 · Cited by 212
Ghanbari Movahed, Z., Rastegari-Pouyani, M., Mohammadi, M. H., & Mansouri, K. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108690 · Cited by 208
AIE-active theranostic system: selective staining and killing of cancer cells
Gui, C., Zhao, E., Kwok, R. T. K., Leung, A. C. S., Lam, J. W. Y., Jiang, M., Deng, H., Cai, Y., Zhang, W., Su, H., et al. (2017) · Chemical Science · doi:10.1039/c6sc04947h · Cited by 212
Redox Regulation of Inflammation: Old Elements, a New Story
Lei, Y., Wang, K., Deng, L., Chen, Y., Nice, E. C., & Huang, C. (2015) · Medicinal Research Reviews · doi:10.1002/med.21330 · Cited by 209
Multi‐Functional Liposome: A Powerful Theranostic Nano‐Platform Enhancing Photodynamic Therapy
Cheng, X., Gao, J., Ding, Y., Lu, Y., Wei, Q., Cui, D., Fan, J., Li, X., Zhu, E., Lu, Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202100876 · Cited by 208
Muhammad, P., Hanif, S., Li, J., Guller, A., Rehman, F. U., Ismail, M., Zhang, D., Yan, X., Fan, K., & Shi, B. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101530 · Cited by 209
New guidelines and definitions for type I photodynamic therapy
Li, M., Xiong, J., Zhang, Y., Yu, L., Yue, L., Yoon, C., Kim, Y., Zhou, Y., Chen, X., Xu, Y., et al. (2025) · Chemical Society Reviews · doi:10.1039/d1cs01079d · Cited by 190
Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells
Pei, S., Minhajuddin, M., Callahan, K. P., Balys, M., Ashton, J. M., Neering, S. J., Lagadinou, E. D., Corbett, C., Ye, H., Liesveld, J. L., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511170 · Cited by 203
Selenium Metabolism and Biosynthesis of Selenoproteins in the Human Body
Minich, W. B. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922140139 · Cited by 189
“An increase in the ROS concentration results in the oxidative stress leading to the damage of nucleic acids, proteins, and lipids and causing numerous pathological processes, such as carcinogenesis [93], neurodegenera tion [94, 95], atherosclerosis, diabetes [96], and aging [97].”
BackgroundMitochondrial ROS and cancer drug resistance: Implications for therapy
Okon, I. S., & Zou, M.-H. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.013 · Cited by 207
Biswas, P., Dey, D., Biswas, P. K., Rahaman, T. I., Saha, S., Parvez, A., Khan, D. A., Lily, N. J., Saha, K., Sohel, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911746 · Cited by 199
“Various research findings demonstrated that cancer cells or rapidly proliferating cells have higher metabolism rates as well as mitochondrial dysfunction along with being more susceptible under oxidizing conditions than healthy cells [11,12].”
Background
Metadata
- Authors
- Trachootham, D., Alexandre, J., & Huang, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Huang, Peng
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-05-29
- Volume
- 8
- Issue
- 7
- Pages
- 579-591
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972779889
- Cited by
- 5,452
- References
- 163
- Citations by year
- 2026: 322 · 2025: 332 · 2024: 340 · 2023: 372 · 2022: 421 · 2021: 462 · 2020: 444 · 2019: 454 · 2018: 393 · 2017: 404 · 2016: 341 · 2015: 289 · 2014: 282 · 2013: 204 · 2012: 158
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA085563, R01CA109041, CA109041, R01CA085563, R01CA100428, CA100428)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- reactive oxygen species, oxidative stress, redox modulation, cancer cells, drug resistance, antioxidant capacity, anticancer agents, genomic instability
- MeSH terms
- Adaptation, Physiological, Animals, Glutathione, Humans, Neoplasms, Oxidation-Reduction, Neoplastic Stem Cells, Reactive Oxygen Species, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.